Asimov will incorporate Minaris’ OXGENE <a center of excellence for advanced viral vector <a proprietary OXGENE technology into its diverse toolkit for AAV Edge producer cell lines, amplifying its synthetic biology <a Minaris is committed to enabling the cell and gene therapy industry through technology partnerships that raise the bar for manufacturing excellence," said Eytan Abraham, Chief Commercial & Technology Officer at Minaris. "We believe in democratization of our technologies and creating a wide variety of solutions to enable the viral vector modality for patients, and are thrilled to enable Asimov in the creation of next‑generation AAV producer cell lines."
Most AAV programs today still rely on transient production, which requires transfecting multiple GMP plasmids for each batch. This method drives up costs, limits scalability, and can lead to variable product quality. Stable production systems for AAV have been difficult to develop because of the complex and interdependent nature of viral genetics. Asimov’s AAV Edge Stable Producer System uses genetic design expertise to overcome this issue and deliver high‑titer, clonal producer cell lines.
“Stable producer cell lines are a key technology to enable AAV gene therapies at scale, and we are excited to partner with Minaris to unlock a new level of performance for our AAV Edge system,” said Raja Srinivas, Co‑Founder at Asimov. “At Asimov, we have developed a genetic design toolkit that allows us to engineer high‑titer cell lines, and we look forward to adding Minaris’s technology to this toolkit and building a production system purpose‑built for the next generation of gene therapies.”
The agreement further solidifies Minaris’ role as an integrated viral vector development and manufacturing partner, merging proprietary OXGENE technologies with its broader development, manufacturing, and testing capabilities that support viral vector programs from early development through commercialization.
About Minaris
Minaris is a global cell and gene therapy (CGT) CDMO and multimodal biosafety testing organization. With more than 25 years of CGT development and manufacturing experience and over 40 years in biosafety testing, Minaris blends deep legacy expertise with state‑of‑the‑art GMP facilities as a fully U.S.-owned company under new ownership and management, positioned for today’s evolving therapeutic landscape.
Through its divisions, Minaris Advanced Therapies and Minaris Advanced Testing, the company assists innovators from IND through commercial supply, providing GMP analytics, biosafety, viral clearance, and product characterization across CGT and biologics. Operating from five global sites across three continents, Minaris is dedicated to helping partners bring more therapies to more patients worldwide.
